news

  • 31 October 2017
    Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

    Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. This year’s SITC is taking place 8 – 12 November, 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland in USA.